Get started
Author

Richard M. Lee‐Ying

Observed names: R Lee-Ying, R. Lee-Ying, R. Lee‐Ying, R. M. Lee-Ying, R.M. Lee-Ying, Richard Lee-Ying, Richard Lee‐Ying, Richard M. Lee-Ying, Richard Marvin Lee-Ying
Observed institutions: Alberta Health Services, BC Cancer Agency, University of British Columbia, University of Alberta, University of Calgary, University of Saskatchewan, Saskatchewan Cancer Agency, Cross Cancer Institute, Arthur J.E. Child Comprehensive Cancer Centre
ORCID: 0000-0003-0913-6046
Observed ORCID: 0000-0003-0913-6046
OpenAlex ID: A5042146146
Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis
2022 · Nicholas A. Bosma, Matthew T. Warkentin, et al. · European Urology Open Science · 94
PDF
PROSPECT Eligibility and Clinical Outcomes: Results From the Pan-Canadian Rectal Cancer Consortium
2016 · Dominick Bossé, Jamison Mercer, et al. · Clinical Colorectal Cancer · 50
Current management and future perspectives of metastatic renal cell carcinoma
2014 · Richard Lee‐Ying, Renee Lester, et al. · International Journal of Urology · 31
The Prognostic Role of the Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer: A Retrospective, Multi-Institutional Study
2018 · Jeenan Kaiser, Haocheng Li, et al. · Bladder Cancer · 27
PDF
Second‐line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real‐world eligibility for cabozantinib, regorafenib, and ramucirumab
2020 · Andrea S. Fung, Vincent C. Tam, et al. · Cancer Medicine · 26
PDF
Autologous transplantation improves survival rates for follicular lymphoma patients who relapse within two years of chemoimmunotherapy: a multi-center retrospective analysis of consecutively treated patients in the real world
2018 · Mita Manna, Richard Lee-Ying, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 23
Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy
2021 · Edoardo Francini, Francesco Montagnani, et al. · JAMA Network Open · 22
PDF
Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database
2018 · Haider H. Samawi, Hao‐Wen Sim, et al. · Cancer Medicine · 20
PDF
A real‐world, population‐based study of patterns of referral, treatment, and outcomes for advanced pancreatic cancer
2018 · Omar Abdel‐Rahman, Yuan Xu, et al. · Cancer Medicine · 17
PDF
Prognostic effect of sidedness in early stage versus advanced colon cancer
2018 · H.F. Kennecke, Y. Yin, et al. · Health Science Reports · 17
PDF
Efficacy of perioperative chemotherapy in resected colorectal liver metastasis: A systematic review and meta-analysis
2021 · Nicholas A. Bosma, Alysha R. Keehn, et al. · European Journal of Surgical Oncology · 16
Effect of sorafenib starting dose and dose intensity on survival in patients with hepatocellular carcinoma: Results from a Canadian Multicenter Database
2020 · Mohammed A. Alghamdi, Carla P. Amaro, et al. · Cancer Medicine · 15
PDF
Impact of Postoperative Adjuvant Chemotherapy Following Long-course Chemoradiotherapy in Stage II Rectal Cancer
2016 · Jonathan M. Loree, Hagen F. Kennecke, et al. · American Journal of Clinical Oncology · 14
Patterns of care for non‐metastatic castration‐resistant prostate cancer: A population‐based study
2022 · Shawn Malone, Christopher J. D. Wallis, et al. · BJUI Compass · 12
Chemotherapy-Related Thrombocytosis: Does It Increase the Risk of Thromboembolism?
2012 · S. Ahmed, R.K. Shahid, et al. · Oncology · 12
Real-world Clinical Outcomes and Prognostic Factors in Neuroendocrine Prostate Cancer
2024 · Richard Gagnon, Ealia Khosh Kish, et al. · Clinical Genitourinary Cancer · 9
PDF
Real world eligibility for cabozantinib (C), regorafenib (Reg), and ramucirumab (Ram) in hepatocellular carcinoma (HCC) patients after sorafenib (S).
2019 · Andrea S. Fung, Vincent C. Tam, et al. · Journal of Clinical Oncology · 9
A Comparison of Survival by Site of Metastatic Resection in Metastatic Colorectal Cancer
2016 · Richard Lee-Ying, Brandon Bernard, et al. · Clinical Colorectal Cancer · 8
Oncology Education for Canadian Internal Medicine Residents: The Value of Participating in a Medical Oncology Elective Rotation
2018 · N.A. Nixon, H. Lim, et al. · Current Oncology · 7
PDF
Active Treatment in Low-Risk Prostate Cancer: A Population-Based Study
2019 · S. Roy, M.E. Hyndman, et al. · Current Oncology · 6
PDF
An Examination of Lymph Node Sampling as a Predictor of Survival in Resected Node-Negative Small Bowel Adenocarcinoma: a SEER Database Analysis
2019 · Maclean Thiessen, R. M. Lee-Ying, et al. · Journal of Gastrointestinal Cancer · 6
Metastasis-free survival as a predictor of overall survival in non-metastatic castration-resistant prostate cancer.
2019 · Richard Gagnon, Nimira S. Alimohamed, et al. · Journal of Clinical Oncology · 6
Dosing, efficacy and safety of lenvatinb in the real‐world treatment of hepatocellular carcinoma: Results from a Canadian database
2022 · Carla Pires Amaro, Michael J. Allen, et al. · Liver Cancer International · 5
PDF
Stage migration of testicular germ cell tumours in Alberta, Canada, during the COVID-19 pandemic: a retrospective cohort study
2022 · Richard Lee-Ying, Dylan E. O’Sullivan, et al. · CMAJ Open · 5
PDF
Impact of primary tumor sidedness on survival after resection of colorectal liver metastases (CRLM).
2017 · Richard M. Lee-Ying, Nicholas Bosma, et al. · Journal of Clinical Oncology · 4
Works count: 114
Citation count: 513
H-index: 13
I10-index: 15
Year
Topic
Type